Insmed (INSM) Stock Price, News & Analysis

Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Key Stats

• Today's Range: $105.75 to $108.89
• 50-Day Range: $66.36 to $107.28
• 52-Week Range: $60.40 to $108.89
• Volume: 2.26 million shs
• Average Volume: 2.76 million shs
• Market Capitalization: $20.62 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $109.20
• Consensus Rating: Buy

Insmed Stock Analysis - MarketRank™

Insmed scored higher than 76% of companies evaluated by MarketBeat, and ranked 233rd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Insmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 17 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Insmed has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Insmed are expected to grow in the coming year, from ($4.56) to ($2.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Insmed is -18.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Insmed is -18.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Insmed has a P/B Ratio of 67.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.11% of the outstanding shares of Insmed have been sold short.

Short Interest Ratio / Days to Cover

Insmed has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Insmed has recently decreased by 1.12%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Insmed does not currently pay a dividend.

Dividend Growth

Insmed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.58

Percentage of Shares Shorted

5.11% of the outstanding shares of Insmed have been sold short.

Short Interest Ratio / Days to Cover

Insmed has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Insmed has recently decreased by 1.12%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.85

News Sentiment

Insmed has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Insmed this week, compared to 13 articles on an average week.

Search Interest

Only 20 people have searched for INSM on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.

MarketBeat Follows

13 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is an increase of 86% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Insmed insiders have sold 27,228.91% more of their company's stock than they have bought. Specifically, they have bought $201,694.00 in company stock and sold $55,120,762.00 in company stock.

Percentage Held by Insiders

Only 3.00% of the stock of Insmed is held by insiders.

INSM Stock Analysis - Frequently Asked Questions

How have INSM shares performed this year?

Insmed's stock was trading at $69.04 at the start of the year. Since then, INSM shares have increased by 57.0% and is now trading at $108.3730.

How were Insmed's earnings last quarter?

Insmed, Inc. (NASDAQ:INSM) announced its earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by $0.06. The firm's quarterly revenue was up 22.9% on a year-over-year basis.
Read the conference call transcript.

Who are Insmed's major shareholders?

Insmed's top institutional shareholders include William Blair Investment Management LLC (0.88%), TD Asset Management Inc (0.21%), Envestnet Asset Management Inc. (0.19%) and Aberdeen Group plc (0.16%). Insiders that own company stock include Melvin Md Sharoky, William Lewis, Roger Adsett, John Drayton Wise, David W J Mcgirr, Orlov S Nicole Schaeffer, Martina MD Flammer, Sara Bonstein, Michael Alexander Smith, Clarissa Desjardins and Clarissa Desjardins.
View institutional ownership trends.

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INSM
• CIK: 1104506
• Web: www.insmed.com
• Phone: 908-977-9900
• Fax: 732-438-0381
• Employees: 1,271
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Insmed: $109.20
• High Price Target: $130.00
• Low Price Target: $96.00
• Potential Upside/Downside: +1.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$913.77 million
• Net Margins: -265.93%
• Pretax Margin: -264.87%
• Return on Equity: -446.98%
• Return on Assets: -52.70%

Debt

• Debt-to-Equity Ratio: 11.38
• Current Ratio: 5.86
• Quick Ratio: 5.44

Sales & Book Value

• Annual Sales: $363.71 million
• Price / Sales: 55.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.60 per share
• Price / Book: 67.05

Miscellaneous

• Outstanding Shares: 189,710,000
• Free Float: 184,022,000
• Market Cap: $20.35 billion
• Optionable: Optionable
• Beta: 0.90